

Literaturverzeichnis

**zum Titelthema „S3-Leitlinie und Nationale Versorgungsleitlinie Unipolare Depression“
von Privatdozentin Dr. Caroline Nothdurfter, Professorin Dr. rer. biol. hum. Dipl.-
Psych. Nina Sarubin, Professor Dr. Thomas C. Wetter, Dr. Thomas C. Baghai und
Professor Dr. Rainer Rupprecht, Bayerisches Ärzteblatt 11/2016, Seite 552 ff.**

1. DGPPN, BÄK, KBV, AWMF, AkdÄ, BpTK, BApK, DAGSHG, DEGAM, DGPs, DGPM, DGRW, S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression, Langfassung, 2. Auflage 2015; Version 3, AWMF-Register-Nr.: nvl-005
2. Ebmeier, K.P., C. Donaghey & J.D. Steele, Recent developments and current controversies in depression. *Lancet* 2006; 367(9505): 153-67.
3. Katon, W.J. et al., Increased medical costs of a population-based sample of depressed elderly patients. *Arch Gen Psychiatry* 2003; 60(9): 897-903.
4. Kessler, R. et al., Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. *Br J Psychiatry Suppl* 1996; 168(Suppl 30): 17-30.
5. Hasin, D. et al., Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. *Arch Gen Psychiatry* 2005; 62(10): 1097-106.
6. Godart, N.T. et al., Comorbidity studies of eating disorders and mood disorders. Critical review of the literature. *J Affect Disord* 2007; 97(1-3): 37-49.
7. Härter, M. et al., Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. *Psychother Psychosom* 2007; 76(6): 354-60.
8. Barth, J., M. Schumacher & C. Herrmann-Lingen, Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. *Psychosom Med* 2004; 66(6): 802-13.
9. Ownby, R.L. et al., Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. *Arch Gen Psychiatry* 2006; 63(5): 530-8.
10. Olfson, M. et al., Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. *Arch Fam Med* 2000; 9(9): 876-83.
11. Deutsche Gesellschaft für Psychiatrie, P.u.N.D., Behandlungsleitlinie Schizophrenie. 2006. (S3 Praxisleitlinien in Psychiatrie und Psychotherapie; 1), Darmstadt: Steinkopff.
12. Geddes, J.R. et al.: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. *Lancet* 2003; 361(9358): 653-61.
13. Nierenberg A A, Amsterdam JD: Treatment-resistant depression: definition and treatment approaches. *J Clin Psychiatry* 1990; 51: 39-47.
14. Stassen HH, Angst J, Hell D, Scharfetter, Szegedi A: Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. *J Clin Psychiatry* 2007; 68: 1195-205.

15. Angst J, Stassen HH: Do antidepressants really take several weeks to show effect? In: Antidepressants, Leonard BE (Editor). 2001, Birkhäuser: Basel, 21-30.
16. Khan A, Khan SR, Leventhal RM, Brown WA: Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. *Int J Neuropsychopharmacol* 2001; 4: 113-8.
17. Cipriani A, Furukawa TA, Salanti G, et al.: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet* 2009; 373: 746-58.
18. Greden JF: Antidepressant maintenance medications: when to discontinue and how to stop. *J Clin Psychiatry* 1993; 54 (Suppl): 39-45.
19. Charney DS, Reynolds CF 3rd, Lewis L et al.: Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. *Arch Gen Psychiatry* 2003; 60: 664-72.
20. Reynolds CF 3rd, Miller MD, Pasternak RE, et al.: Treatment of bereavement-related major depressive episodes in later life: A controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy. *Am J Psychiatry* 1999; 156: 202-8.
21. Reynolds CF 3rd, Frank E, Perel JM, et al.: Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression. A randomized controlled trial in patients older than 59 years. *JAMA* 1999; 28: 39-45.
22. Paykel ES: Continuation and maintenance therapy in depression. *Br Med Bull* 2001; 57: 145-59.
23. Keller MB, Trivedi MH, Thase ME, et al.: The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. *Biol Psychiatry* 2007; 62: 1371-9.
24. Kocsis J, Thase ME, Trivedi MH, et al.: Two years of maintenance treatment with venlafaxine xr 75-225 mg/d: Efficacy in patients with recurrent unipolar major depression. *Eur Psychiatry* 2007; 22: 239-40.
25. Montgomery SA, Huusom AK, Bothmer J: A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. *Neuropsychobiology* 2004; 50: 57-64.
26. Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R: Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. *J Clin Psychiatry* 1998; 59: 229-32.
27. Souza FG, Goodwin GM: Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. *Br J Psychiatry* 1991; 158 (Suppl): 666-75.
28. Baethge C, Gruschka P, Smolka MN, Berghöfer A, Bschor T, Müller-Oerlinghausen B, Bauer M: Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder. *J Psychiatry Neurosci* 2003; 28: 355-61.

29. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G: Lithium for maintenance treatment of mood disorders. *Cochrane Database Syst Rev.* 2001; CD003013.
30. Cowen PJ, Pharmacological management of treatment resistant depression. *Adv Psychiatr Treat* 1998; 4: 320-7.
31. Thase M, Rush A: Treatment-resistant depression. *Psychopharmacology. The fourth generation of progress*, ed. F. Bloom & D. Kupfer. 1995, New York: Raven.
32. Bauer M, Berghöfer A, Adli M: Akute und therapieresistente Depressionen. *Pharmakotherapie-Psychotherapie-Innovationen.* 2005, Springer: Berlin.
33. Licht RW, Qvitzau S: Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. *Psychopharmacology (Berl)* 2002; 161: 143-51.
34. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M: Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. *Eur Arch Psychiatry Clin Neurosci* 2005; 255: 387-400.
35. Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie: Psychotherapie-Richtlinie [online] [Internet]. Jan 6, 2016. Verfügbar unter: <https://www.g-ba.de/informationen/richtlinien/20/>
36. Wampold BE, Minami T, Baskin TW, Tierney SC. A meta - (re) analysis of the effects of cognitive therapy versus „other therapies“ for depression. *J Affect Disord.* 2002;68(2–3):159–65.
37. Tolin DF. Is cognitive–behavioral therapy more effective than other therapies?: A meta-analytic review. *Clin Psychol Rev.* August 2010; 30(6):710–20.
38. DeRubeis RJ, Crits-Christoph P. Empirically supported individual and group psychological treatments for adult mental disorders. *J Consult Clin Psychol.* Februar 1998; 66(1):37–52.
39. Dobson KS. A meta-analysis of the efficacy of cognitive therapy for depression. *J Consult Clin Psychol.* Juni 1989; 57(3):414–9.
40. Gaffan EA, Tsaousis J, Kemp-Wheeler SM. Researcher allegiance and meta-analysis: The case of cognitive therapy for depression. *J Consult Clin Psychol.* Dezember 1995; 63(6):966–80.
41. Gloaguen V, Cottraux J, Cucherat M, Blackburn I-M. A meta-analysis of the effects of cognitive therapy in depressed patients. *J Affect Disord.* April 1998; 49(1):59–72.
42. Spielmanns GI, Berman MI, Usitalo AN. Psychotherapy versus second-generation antidepressants in the treatment of depression: a meta-analysis. *J Nerv Ment Dis.* 2011; 199(3):142–9.
43. Leichsenring F, Leweke F, Klein S, Steinert C. The empirical status of psychodynamic psychotherapy—An update: Bambi's alive and kicking. *Psychother Psychosom.* April 2015; 84(3):129–48.

44. Knekt P, Lindfors O, Härkänen T, Välikoski M, Virtala E, Laaksonen MA, u. a. Randomized trial on the effectiveness of long- and short-term psychodynamic psychotherapy and solution-focused therapy on psychiatric symptoms during a 3-year follow-up. *Psychol Med.* Mai 2008; 38(5):689–703.
45. Knekt P, Lindfors O, Sares-Jäske L, Virtala E, Härkänen T. Randomized trial on the effectiveness of long- and short-term psychotherapy on psychiatric symptoms and working ability during a 5-year follow-up. *Nord J Psychiatry.* Februar 2013; 67(1):59–68.
46. Thase ME, Greenhouse JB, Frank E, Reynolds CFI, Pilkonis PA, Hurley K, u. a. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. *Arch Gen Psychiatry.* November 1997; 54(11):1009–15.
47. Cuijpers P, van Straten A, Schuurmans J, van Oppen P, Hollon SD, Andersson G. Psychotherapy for chronic major depression and dysthymia: A meta-analysis. *Clin Psychol Rev.* Februar 2010; 30(1):51–62.
48. von Wolff A, Hölzel LP, Westphal A, Härter M, Kriston L. Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: A systematic review and meta-analysis. *BMC Psychiatry [Internet].* 13. Juni 2012;12. Verfügbar unter: <http://search.ebscohost.com/login.aspx?direct=true&db=psych&AN=2014-48173-001&site=ehost-live>
49. Cuijpers P, van Straten A, Hollon SD, Andersson G. The contribution of active medication to combined treatments of psychotherapy and pharmacotherapy for adult depression: A meta-analysis. *Acta Psychiatr Scand.* Juni 2010; 121(6):415–23.
50. Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, u. a. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. *JAMA Psychiatry.* 2014; 71(10):1157–64.
51. Kondratyev A, Ved R, Gale K: The effects of repeated minimal electroconvulsive shock exposure on levels of mRNA encoding fibroblast growth factor-2 and nerve growth factor in limbic regions. *Neuroscience* 2002; 114: 411-6.
52. Madsen TM, Treschow A, Bengzon J, Bolwig TG, Lindvall O, Tingström A: Increased neurogenesis in a model of electroconvulsive therapy. *Biol Psychiatry* 2000; 47: 1043-9.
53. Piccinni A, Del Debbio A, Medda P, et al.: Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy. *Eur Neuropsychopharmacol* 2009; 19: 349-55.
54. Malberg JE, Eisch AJ, Nestler EJ, Duman RS: Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci* 2000; 20: 9104-10.
55. Canadian Psychiatric Association, Clinical guidelines for the treatment of depressive disorders. *Canadian Journal of Psychiatry* 2001; 46(Suppl 1): 5S-90S.
56. The UK ECT review group, Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet* 2003; 361: 799-808.

57. Lauritzen L, Odgaard K, Clemmesen L, Lunde M, Ohrström J, Black C, Bech P: Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. *Acta Psychiatr Scand* 1996; 94: 241-51.
58. Mayur PM, Gangadhar BN, Subbakrishna DK, Janakiramaiah N: Discontinuation of antidepressant drugs during electroconvulsive therapy: a controlled study. *J Affect Disord* 2000; 58: 37-41.
59. Grözinger M, et al., Elektrokonvulsionstherapie: Psychiatrische Fachgesellschaften aus vier Ländern empfehlen einen rechtzeitigen und adäquaten Einsatz. *Nervenarzt* 2012; 83: 919-21.
60. Kellner CH, Knapp RG, Petrides G et al.: Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). *Arch Gen Psychiatry* 2006; 63: 1337-44.
61. Brown ED, Lee H, Scott D, Cummings GG: Efficacy of continuation/maintenance electroconvulsive therapy for the prevention of recurrence of a major depressive episode in adults with unipolar depression: a systematic review. *J ECT* 2014; 30: 195-202.
62. Petrides G, Tobias KG, Kellner CH, Rudorfer MV: Continuation and maintenance electroconvulsive therapy for mood disorders: review of the literature. *Neuropsychobiology* 2011; 64: 129-40.
63. Leibenluft E, Wehr TA: Is sleep deprivation useful in the treatment of depression? *Am J Psychiatry* 1992; 149: 159-68.
64. Kuhs H, Tolle R: Sleep deprivation therapy. *Biol Psychiatry* 1991; 29: 1129-48.
65. Wirz-Justice A, van den Hoofdakker RH: Sleep deprivation in depression: what do we know, where do we go? *Biol Psychiatry* 1999; 46: 445-53.
66. Kennedy SH, Lam RW, Cohen NL, Ravindran AV; CANMAT Depression Work Group: Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. *Canadian Journal of Psychiatry* 2001; *Revue canadienne de psychiatrie* 46 Suppl 1: 38S-58S.
67. Kuhs H, Farber D, Tolle R: Serum prolactin, growth hormone, total corticoids, thyroid hormones and thyrotropine during serial therapeutic sleep deprivation. *Biol Psychiatry* 1996; 39: 857-64.
68. Pflug B: The influence of sleep deprivation on the duration of endogenous depressive episodes. *Arch Psychiatr Nervenkr* 1978; 225: 173-7.
69. van den Hoofdakker RH: Chronobiological theories of nonseasonal affective disorders and their implications for treatment. *J Biol Rhythms* 1994; 9: 157-83.
70. Lam RW, Gorman CP, Michalon M et al.: Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. *Am J Psychiatry* 1995; 152: 1765-70.

71. Ruhrmann S, Kasper S, Hawellek B, Martinez B, Höflich G, Nickelsen T, Möller HJ: Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. *Psychol Med* 1998; 28: 923-33.
72. Lee TM, Chan CC: Dose-response relationship of phototherapy for seasonal affective disorder: a meta-analysis. *Acta Psychiatr Scand* 1999; 99: 315-23.
73. Lam RW, Levitt AJ: Canadian consensus guidelines for the treatment of seasonal affective disorder. 1999, Vancouver: Clinical Academic Publ.
74. Tuunainen A, Kripke DF, Endo T: Light therapy for non-seasonal depression. *Cochrane Database Syst Rev* 2004; (2): CD004050.
75. George MS, Lisanby SH, Sackheim HA: Transcranial magnetic stimulation: applications in neuropsychiatry. *Arch Gen Psychiatry* 1999; 56: 300-11.
76. McNamara B, Ray JL, Arthurs OJ, Boniface S: Transcranial magnetic stimulation for depression and other psychiatric disorders. *Psychol Med* 2001; 31: 1141-6.
77. Pascual-Leone A, Rubio B, Pallardó F, Catalá MD: Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. *Lancet* 1996; 348: 233-7.
78. Wassermann EM: Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. *Electroencephalogr Clin Neurophysiol* 1998; 108: 1-16.
79. Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group: Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. *Clin Neurophysiol* 2009; 120: 2008-39.
80. Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ: Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. *Psychol Med* 2014; 44: 225-39.
81. Lefaucheur JP, André-Obadia N, Antal A et al.: Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). *Clin Neurophysiol* 2014; 125: 2150-206.
82. Martin JL, Martin-Sanchez E: Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. *Eur Psychiatry* 2012; 27: 147-55.
83. WHO, Global Recommendations on Physical Activity for Health. WHO Library. http://whqlibdoc.who.int/publications/2010/9789241599979_eng.pdf, 2010.
84. Cooney GM, Dwan K, Greig CA et al.: Exercise for depression. *Cochrane Database Syst Rev*, 2013; 12(9).